Question

Your pharmacy receives its first prescription for a CGRP antagonist for the prevention of migraines. Given that this is a new class of medications, which of the following is NOT a potential clinical outcome of treatment to monitor in patients receiving this medication?

1) Number of migraine days
2) Revenue generated over the first month by dispensing these agents
3) Number of missed days of work due to migraines
4) Opioid use for the reduction of migraine pain

Answer 1

Revenue generated over the first month by dispensing these agents is not a potential clinical outcome to monitor for patients receiving a CGRP antagonist for the prevention of migraines.

Step-by-step explanation:

The subject of this question is Health.

The question is asking which of the following is NOT a potential clinical outcome of treatment to monitor in patients receiving a CGRP antagonist for the prevention of migraines.

Option 2, revenue generated over the first month by dispensing these agents, is NOT a potential clinical outcome of treatment to monitor. This is because revenue generated is a financial outcome and does not directly relate to the efficacy or patient outcomes of the medication.

The potential clinical outcomes to monitor for patients receiving a CGRP antagonist for the prevention of migraines include the number of migraine days, number of missed days of work due to migraines, and opioid use for the reduction of migraine pain.